Literature DB >> 22962380

Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C.

Christina A To1, Robert W Hsieh, James Scott McClellan, Walter Howard, Nancy J Fischbein, Janice M Y Brown, Dean W Felsher, Alice C Fan.   

Abstract

The authors present the first case report of a patient with lymphoma who developed disseminated cryptococcal osteomyelitis and meningitis while being treated with the PEP-C (prednisone, etoposide, procarbazine and cyclophosphamide) chemotherapy regimen. During investigation of fever and new bony lesions, fungal culture from a rib biopsy revealed that the patient had cryptococcal osteomyelitis. Further evaluation demonstrated concurrent cryptococcal meningitis. The patient's disseminated cryptococcal infections completely resolved after a full course of antifungal treatment. Cryptococcal osteomyelitis is itself an extremely rare diagnosis, and the unique presentation with concurrent cryptococcal meningitis in our patient with lymphoma was likely due to his PEP-C treatment. It is well recognised that prolonged intensive chemotherapeutic regimens place patients at risk for atypical infections; yet physicians should recognise that even chronic low-dose therapies can put patients at risk for fungal infections. Physicians should consider fungal infections as part of the infectious investigation of a lymphopaenic patient on PEP-C.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22962380      PMCID: PMC3448757          DOI: 10.1136/bcr.08.2011.4578

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  41 in total

1.  Cryptococcal infection associated with fludarabine therapy.

Authors:  C S Chim; R Liang; S S Wong; K Y Yuen
Journal:  Am J Med       Date:  2000-04-15       Impact factor: 4.965

2.  Isolated cryptococcal sphenoid sinusitis with septicemia, meningitis, and subsequent skull base osteomyelitis in an immunocompetent patient.

Authors:  S Prendiville; S A Bielamowicz; A Hawrych; Z E Deeb
Journal:  Otolaryngol Head Neck Surg       Date:  2000-09       Impact factor: 3.497

3.  Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.

Authors:  P G Pappas; J R Perfect; G A Cloud; R A Larsen; G A Pankey; D J Lancaster; H Henderson; C A Kauffman; D W Haas; M Saccente; R J Hamill; M S Holloway; R M Warren; W E Dismukes
Journal:  Clin Infect Dis       Date:  2001-07-26       Impact factor: 9.079

4.  High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

Authors:  Rena Buckstein; Robert S Kerbel; Yuval Shaked; Rakesh Nayar; Cindy Foden; Ruth Turner; Christine R Lee; Diane Taylor; Liying Zhang; Shan Man; Sylvain Baruchel; Diana Stempak; Francesco Bertolini; Michael Crump
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

5.  A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma.

Authors:  Monika K Krzyzanowska; Ian F Tannock; Gina Lockwood; Jennifer Knox; Malcolm Moore; Georg A Bjarnason
Journal:  Cancer Chemother Pharmacol       Date:  2006-09-29       Impact factor: 3.333

6.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Authors:  Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

7.  Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.

Authors:  Morton Coleman; Peter Martin; Jia Ruan; Richard Furman; Ruben Niesvizky; Rebecca Elstrom; Patricia George; Thomas P Kaufman; John P Leonard
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

8.  Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.

Authors:  L Michael Glode; Albaha Barqawi; Frances Crighton; E David Crawford; Robert Kerbel
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

9.  Prednisone-induced alterations of circulating human lymphocyte subsets.

Authors:  J D Slade; B Hepburn
Journal:  J Lab Clin Med       Date:  1983-03

10.  Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.

Authors:  R Lord; S Nair; A Schache; J Spicer; Navita Somaihah; V Khoo; H Pandha
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.